• $47.2M
    Market Cap
  • -0.56%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry
Annual
Quarterly
12/31/2025
Income Statement
Total Operating Revenue
N/A
N/A
Cost of Revenue
1.0M
N/A
Gross Profit
-1.0M
N/A
Sales and Marketing Expense
272,957
N/A
Research and Development Expense
N/A
N/A
Depreciation and Amortization Expense
2.3M
N/A
Total Operating Expenses
18.1M
N/A
Operating Profit
-7.6M
N/A
Interest Income
N/A
N/A
Interest Expense
-89,089
N/A
Interest Income and Expense and Net
-89,089
N/A
Total Nonoperating Income and Expense
-7.5M
N/A
Income before Taxes
-15.1M
N/A
Income Taxes
-116,385
N/A
Extraordinary Items
N/A
N/A
Net Income
-17.6M
N/A
Net Income from Continuing Operations Applicable to Common
-15.1M
N/A
Basic EPS and Net Income
-0.10
N/A
Diluted EPS and Net Income
-0.10
N/A
Basic Weighted Average Shares
184.9M
N/A
Diluted Weighted Average Shares
184.9M
N/A
Balance Sheet
Cash and Cash Equivalents
2.2M
N/A
Short-Term Investments
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
2.2M
N/A
Total Current Assets
8.1M
N/A
Accumulated Depreciation
6.9M
N/A
Property and Plant and Equipment and Net
N/A
N/A
Total Long-Term Assets
12,605
N/A
Total Assets
36.4M
N/A
Income Taxes Payable
928,566
N/A
Total Short-Term Debt
1.0M
N/A
Total Current Liabilities
8.3M
N/A
Total Long-Term Debt
9.8M
N/A
Total Long-Term Liabilities
13.0M
N/A
Total Liabilities
44.7M
N/A
Retained Earnings
-139.4M
N/A
Total Stockholders Equity
-8.3M
N/A
Total Shares Outstanding
257.9M
N/A
Cash Flow
Cash from Operating Activities
-336,895
N/A
Capital Expenditures
642,014
N/A
Cash from Investing Activities
-749,223
N/A
Dividends Paid
N/A
N/A
Cash from Financing Activities
545,204
N/A
Financials Ratio
Gross Margin
N/A
N/A
Operating Margin
N/A
N/A
Return on Assets
N/A
N/A
Return on Equity
N/A
N/A
Revenue Growth
N/A
N/A
Current Ratio
N/A
N/A
Cash Ratio
N/A
N/A
Debt-to-Equity Ratio
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow